688197 首药控股
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-5.361-16.662-28.777-195.939-206.150
总资产报酬率 ROA (%)-4.895-15.391-25.610-123.473-166.958
投入资产回报率 ROIC (%)-5.347-16.570-28.483-191.191-236.048

边际利润分析
销售毛利率 (%)--97.87199.37199.93299.941
营业利润率 (%)---3,548.333-9,518.597-1,116.806-4,696.104
息税前利润/营业总收入 (%)---3,911.122-10,613.206-1,122.645-4,734.059
净利润/营业总收入 (%)---3,548.792-9,512.739-1,111.996-4,703.466

收益指标分析
经营活动净收益/利润总额(%)106.709107.506114.578112.123101.233
价值变动净收益/利润总额(%)-6.613-3.827-0.6550.000-0.629
营业外收支净额/利润总额(%)0.0000.013-0.062-0.4330.157

偿债能力分析
流动比率 (X)8.50110.89813.4950.6877.170
速动比率 (X)8.49210.89513.4690.6597.047
资产负债率 (%)9.2188.1977.13797.41917.072
带息债务/全部投入资本 (%)0.1030.2210.485-3.823--
股东权益/带息债务 (%)96,561.60245,149.97320,485.261-803.100-1,919.500
股东权益/负债合计 (%)984.7821,119.9701,301.0842.650485.764
利息保障倍数 (X)21.35310.7949.644105.421154.746

营运能力分析
应收账款周转天数 (天)--0.000374.34352.4840.000
存货周转天数 (天)--4,113.77458,806.56685,920.5990.000